Article

Early Detection is as Important as Imatinib in CML Treatment Success

2019-10-18

Abstract excerpt

Chronic myelogenous leukemia (CML) was the first malignancy for which clinical outcome was drastically improved by kinase inhibitor therapy. Kinase inhibitors targeting other well-known oncogenes have been introduced into clinical practice, but none have shown the same magnitude of clinical benefit as ABL1 inhibition in CML. We argue that early detection is an underappreciated, but critically important factor in s...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 15ca1733-c6bb-5448-ba49-98b1ff915878
DOI: 10.20944/preprints201910.0207.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Early Detection is as Important as Imatinib in CML Treatment SuccessDOI 10.20944/preprints201910.0207.v1Read

The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?Semantic proximity Read

The Biology of CML blast crisis.Semantic proximity Read

Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment interventionSemantic proximity Read

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.Semantic proximity Read

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)Semantic proximity Read

Why imatinib remains an exception of cancer researchSemantic proximity Read

New Methodologies in the Molecular Monitoring of CML.Semantic proximity Read

Making progress through molecular attacks on cancer.Semantic proximity Read

Shorter halving time of BCR‐ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic‐phase chronic myeloid leukemia treated with dasatinib: Results of the D‐first study of K anto CML study groupSemantic proximity Read

How I treat CML blast crisisSemantic proximity Read

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.Semantic proximity Read

Wee1 promotes cell proliferation and imatinib resistance in chronic myeloid leukemia via regulating DNA damage repair dependent on ATM-γH2AX-MDC1Semantic proximity Read